Trials / Sponsors / POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Industry · 2 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Terminated | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer | Phase 1 | 2022-07-13 |
| Active Not Recruiting | Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment Metastatic Castration-Resistant Prostate Cancer | Phase 3 | 2021-02-25 |